Market cap
$0 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
0
P/B Ratio
15.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -35.06 | 11.90 | 76.05 | -47.98 | -- |
| EBIT | 48.16 | 71.12 | 46.24 | 3.38 | -11.91 |
| Net Profit | 164.19 | 105.80 | 104.67 | 28.18 | 15.97 |
| EPS | 431.93 | 110.13 | 108.98 | 28.39 | 15.01 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -5,486.75 | -7,224.71 | -1,480.73 | -1,838.36 | -9,135.15 |
| Net Margin
| 4,239.31 | -1,759.43 | 203.13 | -- | 4,239.31 |
| Return on equity
| -126.59 | -1,161.38 | -- | 171.72 | -325.99 |
| Return on Capital
| 148.47 | -375.98 | -- | 775.40 | -177.49 |
| Return on Assets
| -182.02 | -271.76 | 8.11 | -269.01 | -143.32 |
| Debt to Equity (x)
| -- | -- | 0.00 | -0.42 | -1.90 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
775.40
|
-177.49
|
-152.48
|
-312.80
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
171.72
|
-325.99
|
-225.50
|
-1,498.64
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
8.11
Higher than Peers by 5.25
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
8.11
|
-269.01
|
-143.32
|
-133.74
|
-134.45
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
-1,480.73
Lower than Peers by 1,496.56
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
-1,480.73
|
-1,838.36
|
-9,135.15
|
--
|
-9,992.80
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
203.13
Higher than Peers by 194.90
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
203.13
|
-1,719.56
|
4,239.31
|
--
|
-9,756.35
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
76.05
Higher than Peers by 68.00
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
76.05
|
1.73
|
--
|
-1.00
|
--
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
46.24
Higher than Peers by 37.97
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
46.24
|
45.13
|
39.99
|
-228.22
|
-25.97
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
104.67
Higher than Peers by 96.94
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
104.67
|
50.25
|
-12.74
|
-251.37
|
61.85
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
108.98
Higher than Peers by 98.58
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
108.98
|
0.82
|
-0.11
|
-0.79
|
0.81
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
-4.24
Lower than Peers by 9.11
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
-4.24
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
-0.42
|
-1.90
|
0.33
|
3.78
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.36
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
-0.36
|
-0.42
|
-1.12
|
0.02
|
0.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.08
Lower than Peers by 1.57
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
0.08
|
0.14
|
0.90
|
10.07
|
2.35
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
0.08
Lower than Peers by 1.12
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
0.08
|
0.14
|
--
|
--
|
--
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
39.23
Higher than Peers by 34.46
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
39.23
|
-539.99
|
-5,272.29
|
-76.97
|
-228.49
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
9.33
Lower than Peers by 11.94
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
9.33
|
34.63
|
--
|
--
|
--
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.04
Lower than Peers by 0.36
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
0.04
|
0.16
|
0.02
|
--
|
0.03
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
63.25
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
0.01
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
64,171.86
|
18,327.97
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
-64,108.60
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
0.00
Lower than Peers by 37.32
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
0.00
|
-0.36
|
-0.03
|
-0.08
|
-0.15
|
|
Peer Median
|
37.32
|
--
|
--
|
--
|
--
|
Price / Book Value
15.10
Higher than Peers by 7.34
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
15.10
|
-0.41
|
-0.23
|
0.10
|
1.10
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
2.35
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
2.35
|
-0.61
|
-0.10
|
0.88
|
0.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
0
Lower than Peers by 2,521
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Seelos Therapeutics (SEEL)
|
0
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|